AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05417880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hypoglycemic Agents,Oral
Description: Control group with routine current oral hypoglycemic agents for 3-6 months
Study NCT05417880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voreta
Description: Empagliflozin 10 mg oral tablets Once Daily for 3-6 months
Study NCT05417880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voreta plus SunnyD PRO
Description: Empagliflozin 10 mg oral tablets + Vitamin D3 ( 2000 IU ) + Vitamin K2 ( 100 mcg) Once Daily for 3-6 months
Study NCT06451900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: full-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
Study NCT06451900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: ull-term (37 to 41 weeks), Appropriate for gestational age weight between 2500 to 3500 gm infants and with neonatal hyperbilirubinemia not reaching the level of phototherapy were randomised to receive the drug in different doses or in the control group
Study NCT05753787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preservative-free solution of standard post-cataract eye drops
Description: Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
Study NCT05753787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: preservative-free solution of standard post-cataract eye drops
Description: Usage of preservative-free eye drops in comparison to the standard preserved drops with dexamethasone 0.01%.
Study NCT05321680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment withdrawal
Description: Tapering or suspension of antidementia drugs
Study NCT05035472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05035472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05741957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Once-a-week Exercise
Description: Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve one session weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 75 min. Participants will exercise with an exercising heart rate at 6-7 metabolic equivalents (METs). Health information provided to the usual care control group will be made available to the participants in this group.
Study NCT05741957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrice-a-week Exercise
Description: Participants in this group will participate in a supervised treadmill exercise program delivered by certified fitness instructors. The prescribed program will involve three sessions weekly for 4 months, and the duration of vigorous-intensity treadmill exercise per session will be 25 min. Participants will exercise with an exercising heart rate at 6-7 METs. Health information provided to the usual care control group will be made available to the participants in this group.
Study NCT05741957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care Control
Description: Participants in this group will receive health education delivered by research personnel. This program will consist of eight two-hour bi-weekly sessions covering major health issues relating to general health and NAFLD, such as non-communicable diseases, infectious diseases, and a healthy lifestyle.
Study NCT05052086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetomotoric ultrasound
Description: Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
Study NCT04596202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine position
Description: After the infants are treated and fed, they will be given the supine position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
Study NCT04596202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prone position
Description: After the infants are treated and fed, they will be given the prone position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period.
Study NCT04596202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lateral position
Description: After the infants are treated and fed, they will be given the left or right position. After positioning, the residue control will be performed in accordance with the procedure steps guideline at the 30th, 60th and 120th minutes and it will be recorded on residue follow-up form. In addition, the comfort level, heart rate, respiratory rate, and oxygen saturation levels of the infant will be evaluated and recorded at the specified times. At the end of two hours, until the next feeding hour (between 121st-180th minutes), the routine position (supine position) applied in the clinic will be given to the infant and waited in order for physiological parameters and comfort levels to return the period without intervention. The aim here is to ensure for the case to get over the effect of the previous position. No data will be collected within this period. These processes will continue until the 4 positions are completed. Infants will stay in each position for 2 hours.
Study NCT05660200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IBSA Iron ODF
Description: IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.
Study NCT05299554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Hydrocortisone modified-release capsule 5 mg and 10 mg
Study NCT06137859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly-based functional fitness training
Description: Participants will receive a 12-week duration of functional fitness training in daycare centers, which will be implemented twice a week. The 60-minute per session training series will be delivered and guided by qualified elderly health and fitness instructors, who will be provided with a workshop before this intervention. The workshop will be designed and delivered by the research team. The first session will focus on the physical literacy of older adults and the second session will focus on how to lead functional fitness training under the FITT principle for older adults. The main goal of functional training is to improve the range of joint motion, increase muscle strength and flexibility, and boost blood circulation safely. Therefore, symmetry training together with cardiovascular training is the core of the training program. Examples of the main training activities include cardio-full-body exercises, upper-body exercises, lower-body exercises and sensory integrative training.
Study NCT06137859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastering Physical Literacy Class
Description: A 30-minute MPLC program will be conducted by experienced elderly health and fitness instructors after WBFFT. This MPLC program aims to enhance the knowledge and understanding of physical literacy. Referring to the newly developed consensus statement, the MPLC includes the following five domains related to the relationship with movement and physical activity throughout life:~i) Why physical literacy matters - improves health, well-being and quality of life.~ii) Understanding physical literacy - value, enjoy and engage in physical activity for life.~iii) Everyone's physical literacy is different - their individual needs and experiences of movement and physical activity.~iv) Building physical literacy - think, feel, move and connect with others. v) How experience affects physical literacy - people, places and spaces around us.
Study NCT06137859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily based reflective writing
Description: At the end of the baseline stage of this study, each participant of the intervention group will receive a template notebook for daily-based reflective writing. The required columns consist of the daily diet, physical activity, mood and sleep quality. Participants will be required to write down their behavior in this notebook daily. In each week's functional training course, there will be a life-sharing session, where the participants will be reminded to bring their notebooks and share their daily activities with others. They will receive feedback, advice and encouragement from the instructor and each other. The notebook will be collected during the last week of the intervention.
Study NCT06137859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buddy Peers Support Group
Description: Peer-support groups with buddy members will be arranged in each daycare center. Three pairs of buddies and hence about 6 participants will be formed per group. A total of 6 buddy pairs and 2 groups will be formed per daycare center. Buddy peers will encourage each other to do functional exercises regularly or to perform functional exercises together. The time and place for the practice will be decided among buddy members. A member in each group will be nominated as the leader to assist in the liaison and coordination of group activities. The group will perform weekly group-based functional exercises, and the time and place for the practice will be decided among group members. The group will be encouraged to hold monthly gatherings with their fitness instructor in order to strengthen social support.
Study NCT06522087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40Hz stimulation
Description: Exogenous 40HZ stimulation is a physical intervention that can drive oscillations in the gamma range, and the oscillations and pulses caused at the corresponding frequency can lead to a significant reduction in β-amyloid, reverse tau hyperphosphorylation, and thereby improve the cognitive function of patients.
Study NCT04691843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sulfate
Description: Early, high dose, iron supplementation
Study NCT04691843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Sulfate
Description: Early, high dose, iron supplementation
Study NCT05660200 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SiderAL® FORTE
Description: Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.
Study NCT06573983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening (Physical Therapy, Gerofit)
Description: Individuals with physical fall risk will be referred to strengthening interventions available within the VHA. These may include Physical Therapy or Gerofit (a supervised exercise program).
Study NCT06573983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (Clinical Psychology, Occupational Therapy)
Description: Individuals with psychological fall risk will be referred psychological interventions such as cognitive behavioral therapy, which focuses on guided talking. This can be performed by VHA occupational therapists and clinical psychologists.
Study NCT06573983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reconciliation (Clinical Pharmacology)
Description: Individuals with pharmacological fall risk will be referred to clinical pharmacology for medication reconciliation. This includes examining the current medication list and deprescribing medications, if appropriate.
Study NCT06573983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Safety Modification (Occupational Therapy)
Description: Individuals with environmental fall risk will be referred to occupational therapy for home safety assessments and modifications. This will involve modifying components within the home to reduce potential fall risk factors.
Study NCT06312826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal US
Description: The acquired images included B-mode images of the left hepatic lobe through transverse and longitudinal scans including images of the umbilical portion of the left portal vein, and images of the right hepatic lobe through subcostal and intercostal scans including images of the right hepatic dome, right portal vein, and right hepatic vein with additional images of the confluence of both portal vein and three hepatic veins. When a liver observation was seen, additional images were taken, and its diameter was measured on both transverse and longitudinal planes.
Study NCT06312826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMRI
Description: The study subjects receive intravenous injection of gadoxetic acid (0.025 mmol/kg, Primovist; Bayer, Berlin, Germany) in the waiting room and then proceed to the examination room for MRI testing 15-20 minutes later. The MRI examination is conducted using a 3T MRI machine, and the MRI protocol consists of T2-weighted imaging, diffusion-weighted imaging (b value of 0, 50, and 500 s/mm2), and hepatobiliary phase imaging.
Study NCT06442618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Treatment (Group A)
Description: Each session involved a 1:1 ratio of patient to physiatrist. The treatment modality was explained to the patient preliminarily, and before each session, the patients were clinically evaluated and the location of pain was identified.; so patients were asked to assume a comfortable position, and treatment with focal ESWTs was started as per the ISMST protocol
Study NCT06442618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Supplementation (Group B)
Description: Participants in Group B performed home therapy with nutraceutical supplementation containing: hyaluronic acid (200 mg), collagen (5,000 mg), manganese (10 mg) and vitamin C (250 mg), daily for 30 days. Patients were advised to shake the compound, before taking, and to store it at room temperature not exceeding 25 °C, in a cool, dry place, away from light and heat sources. The compound is also free of gluten and lactose, so it can be safely administered.
Study NCT06442618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Treatment (Group C)
Description: Participants in group C were invited to come to our department\&#39;s outpatient clinics to perform treatment with focal ESWT; they had one session every six days for a total of 5 sessions lasting about 20 minutes each. Patients in this group took also additional nutraceutical therapy; they took a daily supplemental treatment of hyaluronic acid, collagen, vitamin C and manganese for 30 days.
Study NCT05604625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Van-Beek activator and a headgear
Description: 12 patients will receive Van-Beek activator and a headgear
Study NCT05604625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Andresen activator
Description: 12 patients will receive Andresen activator.
Study NCT06524674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydration Multiplier + Energy
Description: Participants will be administered one oral serving of an oral rehydration solution containing caffeine and l-theanine
Study NCT06524674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydration Multiplier + Sleep
Description: Participants will be administered one oral serving of an oral rehydration solution containing melatonin and l-theanine
Study NCT06524674 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Energy Comp
Description: Participants will be administered one oral serving of a comparator oral rehydration solution containing caffeine and l-theanine
Study NCT06524674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Comp
Description: Participants will be administered one oral serving of a comparator oral rehydration solution containing melatonin and l-theanine
Study NCT05557331 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PIMPmyHospital (mobile app)
Description: After the implementation of the app, data will be collected prospectively over a 6-month period of use. This will include the times (HH:MM:SS) when the results issued by the central laboratory are made available on caregivers' mobile app and access times (as well as concurrent or preferred access times on the conventional computerized workstations should this occur).
Study NCT05262907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transthoracic Echocardiogram or Cardiac MRI
Description: Non-invasive imaging of the heart to evaluate structure and function.
Study NCT06191367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Description: Aerobic Exercises
Study NCT05262907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventripoint Echocardiogram
Description: Non-invasive ultrasound of the heart to evaluate structure and function through 3D imaging.
Study NCT05613738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
Description: All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Study NCT05613738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01
Description: All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Study NCT05613738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
Description: All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
Study NCT06435104 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neoadjuvant chemotherapy
Description: The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.
Study NCT06435104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy
Description: The neoadjuvant chemotherapy plan will be selected according to the recommendations of the NCCN guidelines and the Chinese CSCO guidelines for early breast cancer.The neoadjuvant chemotherapy plans include:AC-T(HP),TCb(HP),AC-TCb, in which A represents anthracycline, C represents cyclophosphamide, T represents taxane, Cb represents carboplatin, H represents trastuzumab, and P represents pertuzumab.
Study NCT06435104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Patients will inhale essential oils during the neoadjuvant chemotherapy courses.
Study NCT05129943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active distraction
Description: The subject receives the injection of local anesthesia while playing a game on a mobile phone mounted on the VR device using a PS4 controller.
Study NCT05129943 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: passive distraction
Description: The subject receives the injection of local anesthesia while watching a cartoon on a mobile phone mounted on the VR device.
Study NCT05204810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation strategy
Description: For each session of this cross-over study, a different anticoagulation therapy is used: either 1 dose of anticoagulant or 2 doses of anticoagulant